Search

Your search keyword '"Montefiori, David"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Montefiori, David" Remove constraint Author: "Montefiori, David" Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
72 results on '"Montefiori, David"'

Search Results

1. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains

2. A combined adjuvant approach primes robust germinal center responses and humoral immunity in non-human primates

3. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

4. Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques

5. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

6. Direct intranodal tonsil vaccination with modified vaccinia Ankara vaccine protects macaques from highly pathogenic SIVmac251

7. HIV vaccine candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC

8. Author Correction: Long-primed germinal centres with enduring affinity maturation and clonal migration

9. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

10. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial

11. Long-primed germinal centres with enduring affinity maturation and clonal migration

12. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

13. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

14. Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers

15. Defining the risk of SARS-CoV-2 variants on immune protection

16. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

17. High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers

18. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation

19. Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

20. Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features

21. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

22. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

23. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM

24. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

25. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

26. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

27. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles

28. Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center

29. Cold sensitivity of the SARS-CoV-2 spike ectodomain

30. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers

31. Immune checkpoint modulation enhances HIV-1 antibody induction

33. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

34. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations

35. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques

36. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence

37. HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

38. IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells

40. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition

41. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection

42. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations

43. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

44. Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy

46. Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

47. Proceedings of the Frontiers of Retrovirology Conference 2016

48. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Catalog

Books, media, physical & digital resources